Clinical trial
Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole…
NCT00317044 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00317044 |
|---|---|
| Title | Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma |
| Official title | A 6-month Randomized, Double-blind, Parallel-group, Multicentre, Placebo-controlled Phase II Study to Compare Anti-asthmatic Effect and Safety of Esomeprazole (Nexium®) 40 mg Twice Daily or 40 mg Once Daily With Placebo in Adults With Asthma |
| Acronym | RELAX |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Asthma, GERD |
| Intervention type | Drug |
| Interventions | Esomeprazole, Placebo |
| Enrollment | 961 |
| Start date | Apr 1, 2006 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Apr 24, 2006 |
| Last update posted | Jun 9, 2014 |
| Countries | Argentina, Bulgaria, Canada, Czechia, France, Germany, Hungary, Italy, Mexico, Poland, Portugal, Slovakia and 2 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: